TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces the appointment of Mr. David Stolick to its Board of Directors, effective July 28, 2026. Mr. Stolick succeeds
NurExone Biologic Inc. hat die Finanzergebnisse für das erste Quartal 2026 vorgelegt und zugleich ein Update zu jüngsten Aktivitäten und kommenden Meilensteinen gegeben. Das biopharmazeutische Unternehmen entwickelt exosomenbasierte regenerative Therapien und bewegt sich damit in einem Feld, in dem Forschung, Produktion und mögliche klinische Anwendungen eng ineinandergreifen. READ MORE >>>
Canada and Israel-based biopharma company NurExone Biologic Inc. (OTCQB:NRXBF) on Wednesday said its wholly owned U.S. subsidiary, Exo-Top Inc., entered into a binding memorandum of understanding with ExoLyra LLC outlining terms for a proposed exclusive distribution agreement in Mexico for Exo-Top’s naïve mesenchymal stem cell (MSC)-derived exosome products. The companies intend to finalize a definitive agreement
נוראקסון פיתחה טיפול שמשתמש באקסוזומים – חלקיקים זעירים שהגוף מייצר ומשמשים לתקשורת בין תאים – כדי לשקם פגיעות בחוט השדרה ובעצב הראייה שנחשבו עד היום בלתי הפיכות. האם החברה, שצמחה בעקבות שיתוף פעולה בין חוקרים בטכניון ובאוניברסיטת ת”א, תצליח לעבור מחסום שנחשב עד היום לבלתי עביר? READ MORE >>>
TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement
TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce today that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), has entered into a binding
The broader field increasingly recognizes exosomes as regenerative biological particles. NurExone Biologic builds on this foundation in two ways. First, it develops and manufactures naïve exosomes for their intrinsic biological and regenerative properties. Second, it uses proprietary loading technology to add defined therapeutic cargo, converting naïve exosomes into targeted delivery
TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a
